BRIEF-Arqule reports dosing in registrational trial of FGFR inhibitor
November 21, 2017 at 07:08 AM EST
* Arqule announces dosing in a registrational trial of fgfr inhibitor, derazantinib, for treatment of intrahepatic cholangiocarcinoma
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.